{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:21:23Z","timestamp":1789064483702,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00277-025-06368-0","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:49:05Z","timestamp":1744850945000},"page":"2777-2786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic role of interim PET-CT demonstrating partial metabolic response in diffuse large B-Cell lymphoma: a retrospective study"],"prefix":"10.1007","volume":"104","author":[{"given":"Jinjie","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuozi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"issue":"12","key":"6368_CR1","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d\u2019etudes des lymphomes de L\u2019Adulte. Blood 116(12):2040\u20132045","journal-title":"Blood"},{"issue":"3","key":"6368_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1053\/j.semnuclmed.2022.10.004","volume":"53","author":"MN Zeman","year":"2023","unstructured":"Zeman MN, Akin EA, Merryman RW, Jacene HA (2023) Interim FDG-PET\/CT for response assessment of lymphoma. Semin Nucl Med 53(3):371\u2013388","journal-title":"Semin Nucl Med"},{"issue":"3","key":"6368_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12185-019-02690-2","volume":"110","author":"R Nyilas","year":"2019","unstructured":"Nyilas R, Farkas B, Bicsko RR et al (2019) Interim PET\/CT in diffuse large B-cell lymphoma May facilitate identification of good-prognosis patients among IPI-stratified patients. Int J Hematol 110(3):331\u2013339","journal-title":"Int J Hematol"},{"key":"6368_CR4","unstructured":"National Comprehensive Cancer Network clinical practice guidelines in oncology B-cell lymphomas (Version 1.2024)"},{"issue":"10","key":"6368_CR5","doi-asserted-by":"publisher","first-page":"7056","DOI":"10.1007\/s00330-022-08999-7","volume":"32","author":"M Zhao","year":"2022","unstructured":"Zhao M, Kluge K, Papp L et al (2022) Multi-lesion radiomics of PET\/CT for non-invasive survival stratification and histologic tumor risk profiling in patients with lung adenocarcinoma. Eur Radiol 32(10):7056\u20137067","journal-title":"Eur Radiol"},{"issue":"1","key":"6368_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2010-12-327767","volume":"118","author":"RO Casasnovas","year":"2011","unstructured":"Casasnovas RO, Meignan M, Berriolo-Riedinger A et al (2011) SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118(1):37\u201343","journal-title":"Blood"},{"issue":"10","key":"6368_CR7","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.2967\/jnumed.107.042093","volume":"48","author":"C Lin","year":"2007","unstructured":"Lin C, Itti E, Haioun C et al (2007) Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48(10):1626\u20131632","journal-title":"J Nucl Med"},{"issue":"15","key":"6368_CR8","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMra0807082","volume":"362","author":"G Lenz","year":"2010","unstructured":"Lenz G, Staudt LM (2010) Aggressive lymphomas. N Engl J Med 362(15):1417\u20131429","journal-title":"N Engl J Med"},{"issue":"27","key":"6368_CR9","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"27","key":"6368_CR10","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28(27):4184\u20134190","journal-title":"J Clin Oncol"},{"issue":"16","key":"6368_CR11","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800\u20131808","journal-title":"Blood"},{"key":"6368_CR12","doi-asserted-by":"publisher","first-page":"1395824","DOI":"10.3389\/fonc.2024.1395824","volume":"14","author":"C Liao","year":"2024","unstructured":"Liao C, Deng Q, Zeng L et al (2024) Baseline and interim (18)F-FDG PET\/CT metabolic parameters predict the efficacy and survival in patients with diffuse large B-cell lymphoma. Front Oncol 14:1395824","journal-title":"Front Oncol"},{"issue":"1","key":"6368_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00259-018-4103-3","volume":"46","author":"CN Burggraaff","year":"2019","unstructured":"Burggraaff CN, de Jong A, Hoekstra OS et al (2019) Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 46(1):65\u201379","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Supplement 1","key":"6368_CR14","doi-asserted-by":"publisher","first-page":"6439","DOI":"10.1182\/blood-2024-208523","volume":"144","author":"AA Alharbi","year":"2024","unstructured":"Alharbi AA, Alsakkaf A, Alrajhi AM et al (2024) Prognostic value of interim PET\/CT in predicting outcomes of newly diagnosed diffuse large B-Cell lymphoma patients treated with R-CHOP therapy: A retrospective analysis from single centre, Riyadh, Saudi Arabia. Blood 144(Supplement 1):6439\u20136439","journal-title":"Blood"},{"issue":"5","key":"6368_CR15","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1182\/bloodadvances.2020002690","volume":"5","author":"L Kostakoglu","year":"2021","unstructured":"Kostakoglu L, Martelli M, Sehn LH et al (2021) End-of-treatment PET\/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Adv 5(5):1283\u20131290","journal-title":"Blood Adv"},{"issue":"12","key":"6368_CR16","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.2967\/jnumed.114.145326","volume":"55","author":"R Carr","year":"2014","unstructured":"Carr R, Fanti S, Paez D et al (2014) Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-Cell lymphoma. J Nuclear MedicineJ Nucl Med 55(12):1936","journal-title":"J Nuclear MedicineJ Nucl Med"},{"issue":"23","key":"6368_CR17","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1200\/JCO.2014.58.9846","volume":"33","author":"C Mamot","year":"2015","unstructured":"Mamot C, Klingbiel D, Hitz F et al (2015) Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38\/07). J Clin Oncol 33(23):2523\u20132529","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"6368_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2021-148009","volume":"138","author":"SS Neelapu","year":"2021","unstructured":"Neelapu SS, Dickinson M, Munoz J et al (2021) Primary analysis of ZUMA-12: A phase 2 study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line therapy in patients with High-Risk large B-Cell lymphoma (LBCL). Blood 138(Supplement 1):739\u2013739","journal-title":"Blood"},{"issue":"1","key":"6368_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2967\/jnumed.120.244145","volume":"62","author":"J Rekowski","year":"2021","unstructured":"Rekowski J, H\u00fcttmann A, Schmitz C et al (2021) Interim PET evaluation in diffuse large B-Cell lymphoma using published recommendations: comparison of the Deauville 5-Point scale and the \u2206SUV(max) method. J Nucl Med 62(1):37\u201342","journal-title":"J Nucl Med"},{"issue":"9","key":"6368_CR20","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/bloodadvances.2021004467","volume":"5","author":"JJ Eertink","year":"2021","unstructured":"Eertink JJ, Burggraaff CN, Heymans MW et al (2021) Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. Blood Adv 5(9):2375\u20132384","journal-title":"Blood Adv"},{"issue":"2","key":"6368_CR21","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/j.clml.2022.11.009","volume":"23","author":"S Duarte","year":"2023","unstructured":"Duarte S, Roque A, Saraiva T et al (2023) Interim FDG18-PET SUVmax variation adds prognostic value to Deauville 5-Point scale in the identification of patients with Ultra-High-Risk diffuse large B cell lymphoma. Clin Lymphoma Myeloma Leuk 23(2):e107\u2013e116","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"6368_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13550-024-01074-w","volume":"14","author":"W Zhao","year":"2024","unstructured":"Zhao W, Wu X, Huang S, Wang H, Fu H (2024) Evaluation of therapeutic effect and prognostic value of (18)F-FDG PET\/CT in different treatment nodes of DLBCL patients. EJNMMI Res 14(1):20","journal-title":"EJNMMI Res"},{"issue":"11","key":"6368_CR23","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1002\/cam4.2284","volume":"8","author":"YY Zhang","year":"2019","unstructured":"Zhang YY, Song L, Zhao MX, Hu K (2019) A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %\u2206SUV(max). Cancer Med 8(11):5137\u20135147","journal-title":"Cancer Med"},{"issue":"10","key":"6368_CR24","doi-asserted-by":"publisher","first-page":"6789","DOI":"10.21037\/qims-23-251","volume":"13","author":"L Wang","year":"2023","unstructured":"Wang L, Zhang S, Xin J (2023) Predicting diffuse large B-cell lymphoma outcomes with lesion-to-liver maximum standardized uptake value for interim-treatment and end-of-treatment positron emission tomography-computed tomography. Quant Imaging Med Surg 13(10):6789\u20136800","journal-title":"Quant Imaging Med Surg"},{"issue":"4","key":"6368_CR25","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00259-021-05581-z","volume":"49","author":"YH Li","year":"2022","unstructured":"Li YH, Zhao YM, Jiang YL et al (2022) The prognostic value of end-of-treatment FDG-PET\/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV(max) ratio-based evaluation system. Eur J Nucl Med Mol Imaging 49(4):1311\u20131321","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6368_CR26","doi-asserted-by":"crossref","unstructured":"Ferrari C, Pisani AR, Masi T et al (2022) Lesion-to-Liver SUVmax Ratio to Improve the Prognostic Value of the End of Treatment PET\/CT in Diffuse Large B-Cell Lymphoma. J Clin Med. 11(19)","DOI":"10.3390\/jcm11195541"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06368-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06368-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06368-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T06:37:43Z","timestamp":1749105463000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06368-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6368"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06368-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"7 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was carried out using the opt-out method for the case series in our hospital. The study was approved by Peking University Third Hospital Medical Science Research Ethics Committee (approval NO.276\u201301) and was conducted in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was waived by our Institutional Review Board because of the retrospective nature of our study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}